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Dinuclear ruthenium complexes were shown to exhibit strong antiproliferative properties in
human tumor cell lines. In order to extend the structure-activity relationships (SARs), a series of
new RuII(arene)X complexes (X = Cl, Br, I) linked by pyridinone-based spacers were synthesized
and assayed for their in vitro antineoplastic effect. The SARs were established in terms of the arene
ligand, the leaving group (the halide ligand), and the nature and number of the metal centers. It was
demonstrated that, besides the previously shown effect of the spacer length, the nature of the metal
center has the biggest influence on the in vitro anticancer activity. The halide ligand had no effect on
the cytotoxicity, due to rapid formation of the same aquation product for all evaluated compounds.
Furthermore, nearly identical activity was observed when varying the arene ligand from p-cymene to
biphenyl. However, the number of metal centers was found to be important, with the dinuclear
compound being more active than the analogous mono- and trinuclear species.
Introduction
Organometallic complexes have recently gained attention
as antitumor agents1-5 and can be tuned to facilitate the
uptake of the complexes into the cells or for selectivity for
reactions with DNA or proteins.6,7 In order to enable
covalent interaction with biological targets, the compounds
are usually equipped with a halide leaving group, most
frequently a chloride.2,3,6,8-11 Replacement of chloride by
other halides or carboxylates may play a role in the behavior
of such complexes in aqueous solution.12 Furthermore, in
dependence of the electronic properties of the ligands, the
complexes’ properties may be modulated in terms of their
aquation, pKa of the aqua complexes, and nucleobase speci-
ficity (e.g., in [Ru(η6-arene)Cl(ethylenediamine)]PF6,
8,9
RAPTA, and analogous complexes6,10,11,13). Furthermore,
(organometallic) analogues with Os andRhwere assayed for
their tumor-inhibiting properties.14-19
Ruthenium complexes have shown potential as anticancer
agents with high activity in different tumor models. As a
result of tumor selectivity,20 they show low general toxicity,
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and two Ru(III) compounds have reached the stage of
clinical evaluation.21,22
Polynuclear organometallic Ru compounds have been
rarely studied for their anticancer properties, and if they
were assayed, they exhibited lower activity than their mono-
nuclear analogues,23,24 whereas in the case of platinum
complexes the linkage of metal centers has led to the devel-
opment of compounds overcoming resistance of cancer cells
to cisplatin.25-27 We have recently reported on the develop-
ment of dinuclear organometallic compounds28,29 with high
in vitro anticancer activity, whereas the mononuclear mal-
tolato compound was found to be inactive.18 The activity of
compounds initially appeared to be determined by their
lipophilicity;28 however, DNA and protein interaction stu-
dies revealed high potential for DNA-protein and interdu-
plex cross-linking.30
In order to set up structure-activity relationships for
ruthenium(II)-arene complexes with pyridinonato ligands,
the influence of the type ofmetal center and of the leaving halide
ligand aswell as of the nature of the arene groupand thenumber
of metal centers on the antineoplastic activity was studied.
Results and Discussion
Dinuclear Ru(II)-arene complexes with the metal centers
being linked by coordination to alkyl-bridged pyridinone
ligands were shown to exhibit high in vitro antitumor activ-
ity, and studies on their mode of action were reported
previously.28-30 In order to expand the structure-activity
relationships from the mere spacer length to other structural
features, herein the series of dinuclear complexes is extended
to trinuclear compounds, the ruthenium center has been
replaced by Os(II), and the influence of the arene ligand
and the leaving halide is discussed (Figure 1). The new
compounds were obtained by a synthetic route similar to
that described recently.28,29 For the synthesis of the iodido
and bromido complexes the dimeric precursor [(η6-p-cym-
ene)RuCl2]2
31 was converted into [(η6-p-cymene)RuBr2]2
and [(η6-p-cymene)RuI2]2 by treatment with KBr and KI,
respectively. The new compounds were obtained in good to
moderate yields and were characterized by elemental analy-
sis, NMR spectroscopy, and ESI-MS.
Influence of the Metal Center: Ruthenium vs Osmium. In
comparison to numerous Ru(II)-arene complexes, which
were already evaluated for their tumor-inhibiting properties,
only a few Os(II)-arene complexes with anticancer activity
were reported. Recently, Dyson et al. have compared the
effect of replacing Ru by Os in RAPTA-C, a well-explored
drug candidate, and found for Ru and Os only minor dif-
ferences in terms of in vitro anticancer activity, while a struc-
turally related Rh complex was significantly more active.15
A comparison of Os and Ru ethylenediamine complexes
revealed that the Ru compounds are much more active than
their Os analogues,16 whereas in other cases the Os com-
pounds are the more potent agents,32 or both compounds are
equally active as in the case with paullone ligands.33
When the osmium(II) complexes 1a and 2a are compared to
the analogous Ru(II) complexes 1b and 2b, a first obvious
difference between the Ru and Os complexes is a significantly
lower solubility in water of both osmium complexes. Compar-
ison of the aquation by 1H NMR and UV-vis spectroscopy
revealed similarly rapid exchange of the halogenido by aqua
ligands for both Os and Ru complexes. Accordingly, the 1H
NMR spectra of the osmium complexes in D2O did not change
over time (followed for 24 h) or after addition of AgNO3 to
induce the release of the chlorido ligands, also suggesting instant
and quantitative aquation. A kinetic study on the stability of 1a
in water byUV-vis spectroscopy (two absorption bands at 322
and 222 nm) indicated only slight changes within 24 h.
Investigations on the in vitro activity of the osmium
complexes 1a and 2a in the human tumor cell line SW480
have shown a SAR parallel to the analogous ruthenium
complexes:28 a correlation between the chain length and
the cytotoxicity was observed, but the Os complexes are
approximately 3-6 times less active than the Ru analogues
1b and 2b (Table 1). The influence of the metal center was
Figure 1. Chemical formulas of the synthesized mono- and polynuclear ruthenium(II)- and osmium(II)-arene complexes.
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confirmed in a separate panel of human tumor cell lines
(LCLC-103H, A-427, RT-4, MCF-7, DAN-G, 5637). 1a
exhibited IC50 values > 20 μM in all cell lines, whereas 1b
has IC50 values < 20 μM in A-427 and MCF-7 cells.
34
The higher activity of the compounds with longer spacers
may be explained by the higher lipophilicity, as indicated by
the lower water solubility,28,34 but also by different extents of
interaction with DNA and proteins.30 The Os complexes are
significantly more lipophilic than the Ru compounds, and
therefore it is assumed that the generallymore inert nature of
third-row transition metal ions might play an important role
for antineoplastic efficacy. Since hydroxido complexes do
not react as readily as aqua complexes with biomolecules, the
increased propensity of Os complexes to form hydroxido
species at physiological pHmight lower the reactivity toward
biological targets and alter the cellular uptake.18
Influence of theHalide: Chloride vs Bromide vs Iodide. In an
attempt to alter the aquation kinetics and thereby the anti-
cancer activity of dinuclear Ru(II)-arene complexes, the
bromido and iodido compounds 3a and 3b were prepared
and compared to their chlorido analogue 1b. The kinetic
studies on the stability of the bromido and iodido complexes
3a and 3b, respectively, in water by UV-vis spectroscopy
have shown no spectral changes over 24 h. This is similar to
the behavior of 1b, since aquation of the ruthenium com-
plexes was observed within minutes.34 Comparing the 1H
NMR spectra of the chlorido complex 1b and the bromido
complex 3a in CDCl3 (Figure 2) shows for 1b four doublets
for the protons of the p-cymene rings, indicating that the
epimerization of the chiral metal center, leading to none-
quivalent aromatic protons, is sufficiently slow to be ob-
served, whereas the spectrum of 3a contained only two
doublets. In addition, the chemical shift of the aromatic
protons is slightly different. Mixing both CDCl3 solutions
and addition of a small amount of D2O induced a change in
the multiplicity of the aromatic proton signals. This suggests
that the fast aquation results in the formation of a single
product that is identical for both compounds, i.e., {[Ru(p-
cymene)(H2O)]2L}
þ2, which was also confirmed by UV-vis
spectroscopy, with both aquation products showing the
same absorption maximum. A cytotoxicity assay involving
the halide complexes revealed mostly small differences of the
in vitro activity of 1b, 3a, and 3b in SW480 and A2780 cells
(see Table 1). This is likely the effect of rapid aquation, which
leads to the formation of the same products.
Influence of the Arene Group: p-Cymene vs Biphenyl. The
arene ligand is another structural feature that was found to play
an important role in the mode of action and the tumor-growth
inhibition of Ru(II) complexes.35,36 In order to extend the
π-electron ring system of the arene ligand and to enable hydro-
phobicπ-π stacking interactionswithDNAbases, thep-cymene
of ligand of 1b was replaced by biphenyl, leading to the more
lipophilic complex 4. Compound 4 is ca. 6 times less soluble
than 1b, but surprisingly exhibits a similar biological activity
(see Table 1). This result is another indication that the lipophi-
licity does not exclusively determine the antitumor activity of the
compound class. For clarification of SARs, a larger set of
compounds might be required.10,11,35,36 However, for the biphe-
nyl/p-cymene system in [Ru(arene)(en)Cl]þ complexes similar
ratios of IC50 values were reported.
35,36
Influence of the Number of Ruthenium Centers: Mono- vs
Di- vs Trinuclear. The in vitro anticancer activity of 1b, its
closest mononuclear analogue 5, and the trinuclear complex 6
(Figure 1) was compared. In both SW480 and A2780 cells, 1b
was identified as the most active species, while there is no
meaningful difference between the mono- and the trinuclear
complex (seeTable 1).Comparing the lipophilicity of the three
compounds, reflected by their solubility in water, shows that
the mononuclear complex 5 is the most soluble, followed by 6
and 1b (Table 1). The good solubility of 6 is surprising and
might be explained by the presence of a protonable tertiary
amine. The dinuclear compound 1b represents a good com-
promise between solubility and lipophilicity necessary for
cellular uptake. The modification of the compound to link a
higher number of ruthenium moieties improved the water
solubility but decreased the biological effect.
Furthermore, the comparison of the mononuclear pyridi-
nonato compound 5 with the maltolato analogue chlorido-
(maltolato-κO4)(η6-p-cymene)ruthenium(II), 7,18 reveals a
drastically higher in vitro activity for 5 (Table 1).
Conclusions
The influence of modifying the structure of dinuclear Ru-
(II)-arene complexes linked by chelating pyridinone-based
Table 1. Water Solubility and IC50 Values of Ru(II)-Arene
Complexes in Human SW480 and A2780 Cells
IC50/μM
compound solubility/mM SW480 A2780
1a 1.6 88( 4
1ba 3.9 26( 8 30( 6
2a 0.2 15( 5 29( 13
2b 2.2 2.5( 0.2 5.7( 0.5
3a 0.6 54( 4 52( 15
3b 0.1 33( 4 36( 2
4 0.6 25.7( 0.3 43( 1
5 10.3 42( 1 88( 12
6 7.4 59( 18 80( 7
7b >25 >100 >100
aFrom ref 28. bFrom ref 18.
Figure 2. 1HNMR spectra of (a) 1b in CDCl3, (b) 3a in CDCl3,
(c) 1b and 3a in CDCl3, and (d) 1b and 3a in D2O.
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spacers was investigated with regard to tumor-inhibiting
activity in vitro. Taking water solubility as a measure for
lipophilicity, an increase of the latter by extending the spacer
length results in a higher antineoplastic potency in both Os
and Ru compounds. Changing the nuclearity causes a less
pronounced effect on in vitro activity than changing the metal
center from Ru to Os or modifying the spacer length.
Although the trinuclear complex is more water-soluble than
the mononuclear compound, both were found to exhibit
similar antitumor activity. Modifying the leaving group or
changing the arene ligand to a more extended π-electron
system has only minor effects on the in vitro activity. Notably,
replacing the cymene by a biphenyl group causes a significant
change in lipophilicity but does not alter the activity against
cancer cells to a meaningful extent. This shows that factors
other than lipophilicity relevant for the capability of hitting
biomolecular targets, as observed for other non-platinum as
well as for platinum compounds,6,20,37-41 might play an
important role in the mode of action.
Experimental Section
All the chemicals purchased were used without further purifi-
cations. All reactions were carried out in dry solvents and under
argon atmosphere. Bis[dichlorido(η6-biphenyl)ruthenium(II)],42
bis[dichlorido(η6-p-cymene)ruthenium(II)],31 3-benzyloxy-2-
methyl-4-pyrone, 1,6-bis[3-hydroxy-2-ethyl-4(1H)-pyridinon-1-
yl]hexane and 1,8-bis[3-hydroxy-2-ethyl-4(1H)-pyridinon-1-
yl]octane,43 bis[dichlorido(η6-p-cymene)osmium(II)],44 and
chlorido[2-methyl-3-(oxo-κO)-1-propyl-4(1H)-pyridinonato-κO4]-
(η6-p-cymene)ruthenium(II) (5)45 were prepared according to lit-
erature procedures. The dimeric precursor bis[dichlorido(η6-p-
cymene)ruthenium(II)] was converted into bis[dibromido(η6-p-
cymene)ruthenium(II)] and bis[diiodido(η6-p-cymene)ruthenium-
(II)].46 Silica gel (Fluka-60, 70-230 mesh) and silica gel plates
(Polygram SIL G/UV254) were used for preparative and thin-
layer chromatography, respectively.
Melting pointswere determinedwith aB€uchi B-540 apparatus
and are uncorrected. Elemental analyses were carried out with a
Perkin-Elmer 2400 CHN elemental analyzer at the Microana-
lytical Laboratory of the University of Vienna. NMR spectra
were recorded on a Bruker Avance DPX400 spectrometer
(Ultrashield Magnet) at 400.13 (1H) and 100.63 MHz
(13C{1H}) at 25 C in d4-MeOH or in d6-DMSO. Electrospray
ionization (ESI) mass spectra were recorded on a Bruker
Esquire3000 instrument (BrukerDaltonics, Bremen,Germany).
Theoretical and experimental isotope distributions were com-
pared. Ultraviolet-visible (UV-vis) spectra were recorded
on a Perkin-Elmer Lambda 650 instrument from 500 to 200 nm.
Purity of>95% for all compounds was confirmed via elemental
analysis (see Supporting Information).
Syntheses. Bis[dibromido(η6-p-cymene)ruthenium(II)], 10. A
solutionofpotassiumbromide (3.00 g, 25mmol) inwater (20mL)
was added to a solution of bis[dichlorido(η6-p-isopropyltoluol)-
ruthenium(II)] (0.50 g, 0.82 mmol) in chloroform (20 mL), and
the mixture was stirred vigorously for 2 days. The phases were
separated, and a red solid was obtained after evaporation of
chloroform and dried under vacuum.
Yield: 0.51 g (80%), mp 228-230 C. 1H NMR in d4-MeOH:
δ 1.32 [d, 12H, (CH3)2CH,
3J = 6.8 Hz], 2.25 [s, 6H, CH3],
2.80-2.89 [m, 2H, CH(CH3)2], 5.66 [d, 4H, CHarom, 3J = 6.3
Hz], 5.88 [d, 4H, CHarom,
3J=6.3 Hz]. 13C NMR in d4-MeOH:
δ 18.4 [CH3], 21.4 [(CH3)2CH], 31.7 [CH(CH3)2], 78.8 [CH], 79.1
[CH], 90.1 [Carom], 102.6 [Carom].
Bis[diiodido(η6-p-cymene)ruthenium(II)], 10 0. A solution of
potassium iodide (3.25 g, 19.6 mmol) in water (20 mL) was
added to a solution of bis[dichlorido(η6-p-isopropyltoluol)-
ruthenium(II)] (0.60 g, 0.98 mmol) in chloroform (20 mL), and
the mixture was stirred vigorously for 2 days. The phases were
separated, and a dark violet solid was obtained after evapora-
tion of chloroform and dried under vacuum.
Yield: 0.87 g (91%), mp 240-245 C. 1H NMR in d4-MeOH:
δ 1.31 [d, 12H, (CH3)2CH,
3J = 6.8 Hz], 2.35 [s, 6H, CH3],
2.85-2.92 [m, 2H, CH(CH3)2], 5.64 [d, 4H, CHarom, 3J = 6.1
Hz], 5.86 [d, 4H, CHarom,
3J=6.1 Hz]. 13C NMR in d4-MeOH:
δ 19.4 [CH3], 21.8 [(CH3)2CH], 32.1 [CH(CH3)2], 79.3 [CH], 80.1
[CH], 90.1 [Carom], 102.4 [Carom].
2,20,20 0-Tris[3-benzyloxy-2-methyl-4(1H)-pyridinon-1-yl]triethyl-
amine (6a). Sodium hydroxide (1.40 g, 35.0 mmol) was added to a
solutionof 3-benzyloxy-2-methyl-4-pyrone (10.0 g, 46.2mmol) and
tris(2-aminoethyl)amine (1.5 g, 10.3 mmol) in a methanol/water
mixture (2:1, 210 mL). The reaction mixture was refluxed for 48 h
and then allowed to cool to room temperature. The product was
extracted with dichloromethane (3 50mL), and the solvents were
removed under vacuum, yielding a brown oil. The beige product
was obtained by silica gel chromatography with pure methanol.
Yield: 3.05 g (40%), mp 199-200 C. MS (ESIþ): m/z 742
[M þ H]þ. 1H NMR in d4-MeOH: δ 2.20 [s, 9H, CH3], 2.76
[t, 6H, CH2CH2-N,
3J = 6.8 Hz], 3.81 [t, 6H, CH2-N,
3J =
6.8 Hz ], 5.13 [s, 6H, CH2--Ph], 6.46 [d, 3H, CH-CdO, 3J =
7.0 Hz], 7.25-7.42 [m, 15H, CHarom], 7.49 [d, 3H, CH, 3J=7.5
Hz]. 13C NMR in d4-MeOH: δ 12.0 [CH3], 52.0 [CH2CH2-N],
54.2 [CH2-N], 73.3 [CH2-Ph], 116.3 [CH-CdO], 128.4 [CH],
128.4 [CH], 129.3 [CH], 137.5 [Carom], 140.6 [CH], 143.5 [C-
CH3], 146.1 [C-O], 173.9 [CdO].
2,20,200-Tris[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]triethyl-
amine (6b).Hydrogenwaspassed throughasuspensionof6a (0.50g,
0.67 mmol) and palladium on activated carbon (0.10 g) in 100%
acetic acid (40 mL). The conversion was monitored by means of
TLC, and the reaction was terminated as soon as the spot of the
starting compound had disappeared. The catalyst was filtered off,
the solventwas removed, and theproductwasdriedunder vacuum.
Yield: 0.20 g (63%), mp 200-210 C (dec). MS (ESIþ): m/z
471 [MþH]þ. 1H NMR in d6-DMSO: δ 2.27 [s, 9H, CH3], 2.79
[t, 6H, CH2CH2-N, 3J = 6.6 Hz], 3.85 [t, 6H, CH2-N, 3J =
6.6 Hz], 6.09 [d, 3H, CH-CdO, 3J= 7.3 Hz], 7.37 [d, 3H, CH,
3J = 7.3 Hz]. 13C NMR in d6-DMSO: δ 12.3 [CH3], 51.5
[CH2CH2-N], 54.6 [CH2-N], 111.3 [CH-CdO], 129.2 [C-CH3],
139.0 [CH], 146.3 [C-O], 169.8 [CdO].
General Procedure for the Synthesis of the Complexes. A
solution of bis[dichlorido(η6-p-cymene)metal(II)] (metal = os-
mium, ruthenium) in methanol was added to a suspension of
pyridinone ligand and sodium methoxide in methanol. The
reaction mixture was stirred at room temperature for 2-4 days.
The excess of ligand was removed by filtration, and the solvent
was evaporated under vacuum.
1,6-Bis{chlorido[3-(oxo-KO)-2-methyl-4-(1H)-pyridinonato-KO4]-
(η6-p-cymene)osmium(II)}hexane (1a). Bis[dichlorido(η6-p-
cymene)osmium(II)] (202 mg, 0.26 mmol) in methanol (30 mL),
(37) Reedijk, J. Chem. Rev. 1999, 99, 2499–2510.
(38) Sulyok,M.;Hann, S.;Hartinger, C.G.;Keppler, B.K.; Stingeder,
G.; Koellensperger, G. J. Anal. At. Spectrom. 2005, 20, 856–863.
(39) Groessl, M.; Reisner, E.; Hartinger, C. G.; Eichinger, R.;
Semenova,O.; Timerbaev,A.R.; Jakupec,M.A.; Arion, V. B.; Keppler,
B. K. J. Med. Chem. 2007, 50, 2185–2193.
(40) Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler,
B. K.; Dyson, P. J. J. Anal. At. Spectrom. 2007, 22, 960–967.
(41) Casini,A.;Hartinger,C.G.;Gabbiani,C.;Mini, E.;Dyson, P. J.;
Keppler, B. K.; Messori, L. J. Inorg. Biochem. 2008, 102, 564–575.
(42) Morris, R. E.; Sadler, P. J.; Chen, H.; Jodrell, D. Half-sandwich
ruthenium(II) compounds comprising nitrogen containing ligands for
treatment of cancer. 2000-GB4144, 2001.
(43) Harris, R. L. N. Aust. J. Chem. 1976, 29, 1329–1334.
(44) Kiel,W. A.; Ball, R.G.; Graham,W.A.G. J. Organomet. Chem.
1990, 383, 481–496.
(45) Lang, R.; Polborn, K.; Severin, T.; Severin,K. Inorg. Chim. Acta
1999, 294, 62–67.
(46) da Silva, A. C.; Piotrowski, H.; Mayer, P.; Polborn, K.; Severin,
K. Dalton 2000, 2960–2963.
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1,6-bis[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]hexane (100mg,
0.30 mmol), and sodium methoxide (36 mg, 0.66 mmol) in
methanol (30 mL) were used. The complex was extracted with a
dichloromethane/diethyl ether mixture (2:1, 45 mL), the solvent
was removed, and the yellow compound was dried under vacuum.
Yield: 176 mg (66%), mp 248-254 C (dec). MS (ESIþ): m/z
490 [M - 2Cl]2þ. 1H NMR in d4-MeOH: δ 1.29-1.32 [m, 16H,
CH2(CH2)2-N, (CH3)2CH], 1.74 [brs, 4H, CH2CH2-N], 2.31 [s,
6H, CH3], 2.48 [s, 6H, CH3], 2.64-2.73 [m, 2H, CH(CH3)2], 4.09
[t, 4H, CH2-N,
3J=7.5Hz ], 5.87 [d, 4H, CHarom,
3J=5.6 Hz],
6.10 [d, 4H, CHarom,
3J= 5.6 Hz], 6.55 [d, 2H, CH-CdO, 3J=
6.8 Hz], 7.44 [d, 2H, CH, 3J= 6.8 Hz]. 13C NMR in d4-MeOH:
δ 10.9 [CH3], 18.0 [CH3], 22.0 [(CH3)2CH], 25.8 [CH2(CH2)2-N],
30.4 [CH2CH2N], 32.1 [CH(CH3)2], 54.8 [CH2-N], 68.1 [CH],
70.5 [CH], 85.8 [Carom], 86.6 [Carom], 109.0 [CH-CdO], 134.2
[CH], 134.3 [C-CH3], 167.7 [C-O], 175.7 [CdO].
1,8-Bis{chlorido[3-(oxo-KO)-2-methyl-4-(1H)-pyridinonato-KO4]-
(η6-p-cymene)osmium(II)}octane (2a). Bis[dichlorido(η6-p-
cymene)osmium(II)] (199 mg, 0.25 mmol) in methanol (20 mL),
1,8-bis[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]octane (130mg,
0.36 mmol), and sodium methoxide (43 mg, 0.79 mmol) in
methanol (20 mL) were used. The complex was extracted with a
dichloromethane/diethyl ether mixture (2:1, 60 mL), and the
solvent was removed. The compound was dissolved in dichloro-
methane, and a yellow precipitate was obtained by addition of
n-hexane, which was filtered off and dried under vacuum.
Yield: 82 mg (30%), mp 248-250 C (dec). MS (ESIþ): m/z
504 [M - 2Cl]2þ. 1H NMR in d4-MeOH: δ 1.30-1.32 [m, 20H,
CH2(CH2)3-N, CH2(CH2)2-N,(CH3)2CH], 1.73-1.76 [m, 4H,
CH2CH2-N], 2.32 [s, 6H,CH3)], 2.49 [s, 6H,CH3], 2.67-2.74 [m,
2H, CH(CH3)2], 4.11 [t, 4H, CH2-N,
3J= 7.8 Hz], 5.90 [d, 4H,
CHarom,
3J=5.6Hz], 6.12 [d, 4H,CHarom,
3J=5.3Hz], 6.58 [d,
2H, CH-CdO, 3J=6.8 Hz], 7.47 [d, 2H, CH, 3J=6.8 Hz]. 13C
NMR in d4-MeOH: δ 10.9 [CH3], 18.1 [CH3], 22.1 [(CH3)2CH],
26.1 [CH2(CH2)3-N], 28.9 [CH2(CH2)2-N], 30.6 [CH2CH2-N],
32.1 [CH(CH3)2], 55.0 [CH2-N], 68.2 [CH], 70.6 [CH], 84.9
[Carom], 86.5 [Carom], 108.9 [CH-CdO], 134.2 [CH], 134.3 [C-
CH3], 161.8 [C-O], 175.7 [CdO].
1,6-Bis{bromido[3-(oxo-KO)-2-methyl-4-(1H)-pyridinonato-KO4]-
(η6-p-cymene)ruthenium(II)}hexane (3a). Bis[dibromido(η6-p-
cymene)ruthenium(II)] (184mg, 0.23mmol) inmethanol (20mL),
1,6-bis[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]hexane (103mg,
0.31 mmol), and sodium methoxide (37 mg, 0.68 mmol) in
methanol (20 mL) were used. The complex was extracted with
a dichloromethane/diethyl ether mixture (2:1, 45 mL), and the
solvent was removed. The compound was dissolved in dichloro-
methane, precipitated by addition of n-hexane, filtered off, and
dried under vacuum.
Yield: 85 mg (38%), mp 130-135 C. MS (ESIþ): m/z 401
[M - 2Br]2þ. 1H NMR in d4-MeOH: δ 1.31-1.34 [m, 16H,
CH2(CH2)2-N, (CH3)2CH], 1.70 [brs, 4H, CH2CH2-N], 2.29
[s, 6H, CH3], 2.46 [s, 6H, CH3], 2.82-2.90 [m, 2H, CH(CH3)2],
4.04 [t, 4H, CH2-N,
3J=7.5 Hz], 5.43 [d, 4H, CHarom,
3J=5.8
Hz], 5.64 [d, 4H, CHarom,
3J= 5.8 Hz], 6.48 [d, 2H, CH-CdO,
3J = 6.8 Hz], 7.38 [d, 2H, CH, 3J = 6.8 Hz]. 13C NMR in d4-
MeOH: δ 10.8 [CH3], 17.7 [CH3], 21.6 [(CH3)2CH], 25.8
[CH2(CH2)2-N], 30.4 [CH2CH2N], 31.4 [CH(CH3)2], 54.8
[CH2-N], 78.1 [CH], 79.5 [CH], 95.8 [Carom], 99.1 [Carom],
109.3 [CH-CdO], 133.6 [CH], 134.1 [C-CH3], 162.5 [C-O],
174.1 [CdO].
1,6-Bis{iodido[3-(oxo-KO)-2-methyl-4-(1H)-pyridinonato-KO4]-
(η6-p-cymene)ruthenium(II)}hexane (3b). Bis[diiodido(η6-p-
cymene)ruthenium(II)] (309 mg, 0.32 mmol) in methanol (25 mL),
1,6-bis[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]hexane (150 mg,
0.45mmol), and sodiummethoxide (54mg, 0.99mmol) inmethanol
(25 mL) were used. The complex was extracted with a dichloro-
methane/diethyl ether mixture (2:1, 65 mL), and the solvent was
removed. The compound was dissolved in dichloromethane, pre-
cipitated by addition of n-hexane, filtered off, and dried under
vacuum.
Yield: 255 mg (77%), mp 128-130 C. MS (ESIþ): m/z 401
[M - 2I]2þ. 1H NMR in d4-MeOH: δ 1.32-1.34 [m, 16H,
CH2(CH2)2-N, (CH3)2CH], 1.70 [brs, 4H, CH2CH2-N], 2.32 [s,
6H, CH3], 2.43 [s, 6H, CH3], 2.88-2.95 [m, 2H, CH(CH3)2], 4.04
[t, 4H, CH2-N, 3J=6.8Hz], 5.42 [d, 4H, CHarom, 3J=6.1Hz],
5.62 [d, 4H, CHarom,
3J= 6.1 Hz], 6.44 [d, 2H, CH-CdO, 3J=
6.8 Hz], 7.40 [d, 2H, CH, 3J= 6.8 Hz]. 13C NMR in d4-MeOH:
δ 10.9 [CH3], 18.3 [CH3], 21.8 [(CH3)2CH], 25.7 [CH2(CH2)2-N],
30.4 [CH2CH2N], 31.6 [CH(CH3)2], 54.7 [CH2-N], 78.7 [CH],
79.6 [CH], 84.9 [Carom], 95.3 [Carom], 109.2 [CH-CdO], 133.5
[CH], 133.9 [C-CH3], 167.7 [C-O], 188.4 [CdO].
1,6-Bis{chlorido[3-(oxo-KO)-2-methyl-4-(1H)-pyridinonato-KO4]-
(η6-biphenyl)ruthenium(II)}hexane (4). Bis[dichlorido(η6-
biphenyl)ruthenium(II)] (147 mg, 0.23 mmol) in dichloromethane
(25mL),1,6-bis[3-hydroxy-2-methyl-4(1H)-pyridinon-1-yl]hexane
(100mg, 0.30mmol), and sodiummethoxide (36mg, 0.66mmol) in
dichloromethane (25 mL) were used. The complex was extracted
with a dichloromethane/diethyl ethermixture (2:1, 65mL), and the
solvent was removed. The compound was dissolved in dichloro-
methane, precipitated by addition of n-hexane, filtered off, and
dried under vacuum.
Yield: 95 mg (46%), mp 188-190 C. MS (ESIþ): m/z 421
[M - 2Cl]2þ. 1H NMR in d4-MeOH: δ 1.30 [brs, 4H, CH2-
(CH2)2-N], 1.67 [brs, 4H, CH2CH2-N], 2.40 [s, 6H, CH3], 4.03
[t, 4H, CH2-N,
3J= 7.5 Hz], 5.91-5.94 [m, 6H, CHarom], 6.10
[d, 4H, CHarom,
3J= 5.6 Hz], 6.46 [d, 2H, CH-CdO, 3J= 6.8
Hz], 7.37 [d, 2H, CH, 3J=6.8 Hz], 7.46-7.48 [m, 6H, CHarom],
7.83 [m, 4H, CHarom].
13CNMR in d4-MeOH: δ 10.8 [CH3], 25.7
[CH2(CH2)2-N], 30.4 [CH2CH2N], 54.7 [CH2-N], 78.8 [CH],
80.7 [CH], 80.9 [CH], 94.4 [Carom], 109.4 [CH-CdO], 128.9
[CH], 129.6 [CH], 132.1 [Carom], 133.8 [CH], 134.4 [C-CH3],
159.4 [C-O], 173.8 [CdO].
2,20,200-Tris[chlorido[3-(oxo-KO)-2-methyl-4(1H)-pyridinonato-
KO4](η6-p-cymene)ruthenium(II)]triethylamine (6c). Bis[dichlo-
rido(η6-p-cymene)ruthenium(II)] (166 mg, 0.27 mmol) in metha-
nol (20 mL), pyridinone 6b (100 mg, 0.21 mmol), and sodium
methoxide (38mg, 0.7mmol) inmethanol (20mL)were used. The
complex was extracted with a dichloromethane/diethyl ether
mixture (2:1, 65 mL), and the solvent was removed. The com-
pound was dissolved in dichloromethane, precipitated by addi-
tion of n-hexane, filtered off, and dried under vacuum.
Yield: 150 mg (55%), mp 258-260 C (dec). MS (ESIþ): m/z
1245 [M-Cl]þ, 604 [M- 2Cl]2þ, 392 [M- 3Cl]3þ. 1HNMR in
d4-MeOH: δ 1.31 [d, 18H, (CH3)2CH,
3J=6.8 Hz], 2.25 [s, 9H,
CH3], 2.41 [s, 9H, CH3], 2.74 [brs, 6H, CH2CH2-N], 2.80-
2.87 [m, 3H, CH(CH3)2,], 3.78 [brs, 6H, CH2-N], 5.39 [d, 6H,
CHarom,
3J= 4.8 Hz], 5.62 [d, 6H, CHarom,
3J= 5.0 Hz], 6.38
[d, 3H, CH-CdO, 3J= 4.3 Hz], 6.85 [d, 3H, CH, 3J= 5.3 Hz].
13C NMR in d4-MeOH: δ 11.1 [CH3], 17.6 [CH3], 21.6
[(CH3)2CH], 31.4 [CH(CH3)2], 52.8 [CH2CH2-N], 54.4 [CH2-
N], 78.0 [CH], 79.7 [CH], 95.9 [Carom], 99.1 [Carom], 109.3 [CH-
CdO], 133.3 [C-CH3], 134.5 [CH], 159.8 [C-O], 174.5 [CdO].
Aquation. The aquation was studied using UV-vis and 1H
NMRspectroscopy.TheUV-vis spectrawere recorded from200
to 500 nm at concentrations of 0.5 mM complex, and the process
was followed for 24 h using a Perkin-Elmer Lambda
650 instrument. For NMR spectroscopy, samples were dissolved
in H2O/D2O (9:1) at 25 C, and 1HNMR spectra were recorded.
ExperimentalProtocol forCellCultureStudies. CellLines and
Cell Culture Conditions.Human SW480 (colon adenocarcinoma)
and A2780 (ovarian carcinoma) cells were kindly provided by
BrigitteMarian (Institute ofCancerResearch,MedicalUniversity
of Vienna, Austria) and Evelyn Dittrich (General Hospital, Med-
ical University of Vienna, Austria), respectively. Cells were grown
in 75 cm2 culture flasks (Iwaki/Asahi Technoglass, Gyouda,
Japan) as adherent monolayer cultures in complete culture med-
ium, i.e., minimal essential medium (MEM) supplemented with
10% heat-inactivated fetal bovine serum, 1 mM sodium pyru-
vate, 4 mM L-glutamine, and 1% nonessential amino acids
(100) (all purchased from Gibco/Invitrogen, Paisley, UK)
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without antibiotics. The cell lines 5637 andRT-4 (bladder cancer),
LCLC-103H and A-427 (lung cancer), DAN-G (pancreatic
cancer), and MCF-7 (breast cancer) were obtained from the
German Collection of Microorganisms and Cell Culture
(DSMZ, Braunschweig, FRG). The three oxoplatin-resistant cell
lines were established at the University of Greifswald through
weekly exposure of cells to increasing concentrations of oxoplatin
over a period of several months. These cells were grown in culture
flasks (Sarstedt,Germany) as adherentmonolayer cultures in 90%
RPMI medium supplemented with 10% heat-inactivated fetal
bovine serum and the antibiotics benzylpenicillin and strepto-
mycin. To the medium for the MCF-7 cells were added 1 mM
sodium pyruvate and 1% nonessential amino acids. All cultures
were maintained at 37 C in a humidified atmosphere containing
5% CO2.
MTTAssayConditions.Cytotoxicitywasdeterminedbymeans
of a colorimetric microculture assay [MTT assay,MTT=3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide]. For
this purpose, SW480 andA2780 cells were harvested from culture
flasks by trypsinization and seeded into 96-well microculture
plates (Iwaki/Asahi Technoglass, Gyouda, Japan) in densities of
2.5  103 and 5.0 103 cells/well, respectively, in order to ensure
exponential growth throughout drug exposure.Cellswere allowed
to settle in drug-free complete culture medium for 24 h, followed
by the addition of dilutions of the test compounds in 100 μL/well
complete culture medium and incubation for 96 h. Compounds
with low water solubility were stored in DMSO stock solutions,
which were diluted with medium such that the effective DMSO
content did not exceed 1%.At the end of exposure, drug solutions
were replaced by 100 μL/well RPMI 1640 culture medium
(supplemented with 10% heat-inactivated fetal bovine serum
and 2 mM L-glutamine) and 20 μL/well MTT solution in phos-
phate-buffered saline (5 mg/mL). After incubation for 4 h, the
medium/MTTmixtures were removed, and the formazan crystals
formed by vital cells were dissolved in 150 μL of DMSO per well.
Optical densities at 550 nm were measured with a microplate
reader (Tecan Spectra Classic) using a reference wavelength of
690nm to correct for unspecific absorption.Quantities of vital cells
were expressed in terms of T/C values by comparison to untreated
controls, and 50% inhibitory concentrations (IC50) were calcu-
lated from concentration-effect curves by interpolation. Evalua-
tion is based on means from at least three independent experi-
ments, each comprising six replicates per concentration level.
Crystal Violet Assay Conditions.This assay has been described
in detail elsewhere.47 Culture conditions were the same as used in
the MTT assay. Briefly, cells were seeded into 96-well micro-
culture plates (Sarstedt, FRG) in cell densities of 1.0  103 cells/
well, except for LCLC-103H, which was seeded at 250 cells/well.
After a 24 h preincubation, cells were treated with the test
substance for 96 h. Stock solutions of test substance were
prepared to 20 mM in DMF and diluted 1000-fold in RPMI
1640 culturemediumcontaining 10%fetal calf serum.Substances
that showed a g50% growth inhibition at 20 μM were tested at
5 serial dilutions in 4 wells/concentration to determine the IC50
values as described.47 Staining of cells was done for 30min with a
0.02%crystal violet solution inwater followedbywashing out the
excess dye. Cell-bound dye was redissolved in 70% ethanol/water
solution, and the optical densities at λ= 570 nm were measured
with a microplate reader (Anthos 2010).
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Cancer Drugs 2006, 17, 41–51.
D
ow
nl
oa
de
d 
by
 E
PF
 L
A
U
SA
N
N
E 
on
 N
ov
em
be
r 3
, 2
00
9 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Oc
tob
er 
15
, 2
00
9 | 
doi
: 1
0.1
021
/om
900
715
j
